TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22758350

Group type: EXPERIMENTAL
Intervention: Non-pesticide-based shampoo
Number of subjects: 216

Group type: COMPARATOR
Intervention: Malathion foam
Number of subjects: 216
Study: 19121428

Group type: EXPERIMENTAL
Intervention: Complete ST resolution
Number of subjects: 3425

Group type: EXPERIMENTAL
Intervention: Partial ST resolution
Number of subjects: 3425

Group type: EXPERIMENTAL
Intervention: No ST resolution
Number of subjects: 3425
Study: 17312209

Group type: EXPERIMENTAL
Intervention: Sugammadex 2.0 mg/kg administered by IV bolus after rocuronium-induced NMB under propofol anesthesia
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Sugammadex 2.0 mg/kg administered by IV bolus after rocuronium-induced NMB under sevoflurane anesthesia
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (sevoflurane)
Number of subjects: 42
Study: 15353025

Group type: EXPERIMENTAL
Intervention: Qigong exercise (two 30-minute sessions per week for 8 weeks)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 36
Study: 11280691

Group type: EXPERIMENTAL
Intervention: Educational sessions run by local opinion leaders presenting guidelines on management of UAP from the National Health and Medical Research Council.
Number of subjects: 1872
Study: 9557590

Group type: EXPERIMENTAL
Intervention: Inspiratory resistance of 0.20 kPa (R1)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Inspiratory resistance of 0.29 kPa (R2)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Inspiratory resistance of 0.39 kPa (R3)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Inspiratory resistance of 0.49 kPa (R4)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 9
Study: 8012746

Group type: EXPERIMENTAL
Intervention: Resource loss
Number of subjects: 229
Study: 3221375

Group type: EXPERIMENTAL
Intervention: Sustained-release verapamil 240 mg tablets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Office BP measurement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Day-time ambulatory monitoring
Number of subjects: 0
Study: 30786304

Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg of pethidine
Number of subjects: 200

Group type: COMPARATOR
Intervention: 25 mg/kg of dipyrone
Number of subjects: 200
Study: 27940313

Group type: EXPERIMENTAL
Intervention: Stressful condition (BE group)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Non-stressful condition (BE group)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Stressful condition (HC group)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Non-stressful condition (HC group)
Number of subjects: 103
Study: 26405294

Group type: EXPERIMENTAL
Intervention: Nebulised colistin (500000 U, thrice daily for 10 days)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Normal saline (NS group, thrice daily for 10 days)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Nebulised colistin
Number of subjects: 168
Study: 23849900

Group type: EXPERIMENTAL
Intervention: Exercise with heat/steam generating sheet (Ex+HSGS)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Heat/steam generating sheet (HSGS)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Exercise (Ex)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Health education (HE)
Number of subjects: 150
Study: 17001471

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg once daily
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Sitagliptin 200 mg once daily
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 521

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 521
Study: 14612477

Group type: EXPERIMENTAL
Intervention: Rofecoxib (50 mg oral at 24 hours and 1-2 hours before TKA, 50 mg daily for 5 days postoperatively, and 25 mg daily for another 8 days)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 10469966

Group type: EXPERIMENTAL
Intervention: Posterior pericardiotomy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control (no posterior pericardiotomy)
Number of subjects: 200
Study: 9122013

Group type: EXPERIMENTAL
Intervention: Serum TNF-alpha (SeTNF)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Urinary TNF-alpha (UTNF)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Serum IL-6 (SeIL-6)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Urinary IL-6 (UIL-6)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Antibiotics therapy
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: High urinary levels of IL-6 and/or TNF-alpha
Number of subjects: 99
Study: 1812424

Group type: EXPERIMENTAL
Intervention: Meningococcal outer membrane vesicle serogroup B vaccine (MenB‐vaccine "Folkehelsa")
Number of subjects: 221
Study: 6615664

Group type: EXPERIMENTAL
Intervention: Labetalol (200 mg twice daily for five days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31326340

Group type: EXPERIMENTAL
Intervention: Preemptive extensive rotator interval release (group 1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: RI nonrelease (group 2)
Number of subjects: 80
Study: 29116303

Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation (TMS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study: 26345529

Group type: EXPERIMENTAL
Intervention: Respiratory rehabilitation exercise training (twice a day, 10-30 minutes per session for 4 days)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 61
Study: 23532747

Group type: EXPERIMENTAL
Intervention: Agomelatine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluoxetine, Sertraline, Venlafaxine
Number of subjects: 0
Study: 21784328

Group type: EXPERIMENTAL
Intervention: Usual care plus individualised homeopathy (HC)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 39
Study: 19931760

Group type: EXPERIMENTAL
Intervention: Over-the-head CPR
Number of subjects: 21

Group type: COMPARATOR
Intervention: Standard CPR
Number of subjects: 21
Study: 16950948

Group type: EXPERIMENTAL
Intervention: Spring dosing schedule of trivalent inactivated influenza vaccine
Number of subjects: 468

Group type: COMPARATOR
Intervention: Fall dosing schedule of trivalent inactivated influenza vaccine
Number of subjects: 468
Study: 15258384

Group type: EXPERIMENTAL
Intervention: Ascovertin
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (no Ascovertin)
Number of subjects: 31
Study: 11374008

Group type: EXPERIMENTAL
Intervention: Sibutramine (10 mg/day)
Number of subjects: 605

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 605
Study: 8980210

Group type: EXPERIMENTAL
Intervention: Clinical history supplied for the first reading
Number of subjects: 100

Group type: COMPARATOR
Intervention: Clinical history omitted for the second reading
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sham history shown to 5 cases
Number of subjects: 100
Study: 8077310

Group type: EXPERIMENTAL
Intervention: Cortisol (2 micrograms/kg.min)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 8
Study: 3608345

Group type: EXPERIMENTAL
Intervention: Bumetanide 2mg orally (as tablets)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Bumetanide 2mg intravenously
Number of subjects: 6
Study: 31900134

Group type: EXPERIMENTAL
Intervention: CVD risk assessment and communication by nurses for primary prevention of CVDs
Number of subjects: 902

Group type: EXPERIMENTAL
Intervention: CVD risk assessment and communication by nurses for secondary prevention of CVDs
Number of subjects: 902
Study: 29371234

Group type: EXPERIMENTAL
Intervention: Behavioral intervention to improve diet quality over 18 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disordered eating behaviors (DEB)
Number of subjects: 0
Study: 26990655

Group type: EXPERIMENTAL
Intervention: Multiple imputation methods
Number of subjects: 0

Group type: COMPARATOR
Intervention: Complete case analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fixed-effects multiple imputation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single-level multiple imputation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multilevel multiple imputation
Number of subjects: 0
Study: 25621429

Group type: EXPERIMENTAL
Intervention: Hydrocodone (HC)
Number of subjects: 0
Study: 23605377

Group type: EXPERIMENTAL
Intervention: Community Windshield Tours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-/post-tour surveys
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long-term follow-up surveys
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: REACH activities
Number of subjects: 0
Study: 20195575

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 19368098

Group type: EXPERIMENTAL
Intervention: Intensive glycaemic control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lifestyle modification plus combinations of insulin sensitisers and insulin secretagogues
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Incretin mimetics or insulin
Number of subjects: 0
Study: 16736339

Group type: EXPERIMENTAL
Intervention: Intraoperative blood salvage (IBS) with transfusion of both allogeneic and autologous blood
Number of subjects: 44

Group type: COMPARATOR
Intervention: Allogeneic blood transfusion at the discretion of the attending medical staff
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Intraoperative blood salvage (IBS)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Allogeneic blood transfusion
Number of subjects: 44
Study: 12669748

Group type: EXPERIMENTAL
Intervention: Bimanual reaching movements with targets of the same color
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bimanual reaching movements with targets of different colors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unimanual movements presented among distractors associated with responses for the other hand
Number of subjects: 0
Study: 10809299

Group type: EXPERIMENTAL
Intervention: Continuous venovenous hemofiltration (CVVH)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Continuous venovenous hemodiafiltration (CVVHD)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: CVVH
Number of subjects: 6

Group type: COMPARATOR
Intervention: CVVHD
Number of subjects: 6
Study: 8857005

Group type: EXPERIMENTAL
Intervention: Intralesional injections of hCG (250, 500, 1000, or 2000 IU) three times a week for two weeks.
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intralesional injections of 2000 IU of hCG.
Number of subjects: 36

Group type: COMPARATOR
Intervention: Diluent alone (control group).
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Intralesional injections of hCG.
Number of subjects: 36
Study: 1350495

Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Benzhexol (5 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Haloperidol (1 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Caffeine (400 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 6368614

Group type: EXPERIMENTAL
Intervention: 50 mg propiram fumarate
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: 650 mg aspirin
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: 60 mg codeine phosphate
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study: 30381313

Group type: EXPERIMENTAL
Intervention: Multicomponent m-Health behaviour change weight loss intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enhanced intervention (physical activity, dietary behaviour and sleep intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Traditional intervention (physical activity and dietary behaviour only)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 0
Study: 26564024

Group type: EXPERIMENTAL
Intervention: Cinacalcet
Number of subjects: 3883

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3883
Study: 24995191

Group type: EXPERIMENTAL
Intervention: Propofol and Ketamine (PK)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Propofol and Fentanyl (PF)
Number of subjects: 60
Study: 23318236

Group type: EXPERIMENTAL
Intervention: Eco-friendly vector control programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control clusters
Number of subjects: 0
Study: 20117554

Group type: COMPARATOR
Intervention: 2-year ecologic intervention to prevent weight gain through changes in worksite weight-related norms.
Number of subjects: 806

Group type: COMPARATOR
Intervention: Intervention participation (scale=0 to 100) as independent variable.
Number of subjects: 806

Group type: EXPERIMENTAL
Intervention: Intervention sites
Number of subjects: 806

Group type: COMPARATOR
Intervention: Control sites
Number of subjects: 806
Study: 17013567

Group type: EXPERIMENTAL
Intervention: Teriparatide 20 mcg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Teriparatide 40 mcg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Teriparatide (20 or 40 mcg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Teriparatide (40 mcg/day)
Number of subjects: 0
Study: 15823826

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE) 0.625 mg/day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE) 0.625 mg/day plus medroxyprogesterone acetate (MPA) 2.5 mg/day
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA) 5.0 mg/day
Number of subjects: 30
Study: 11990920

Group type: EXPERIMENTAL
Intervention: Nasojejunal feeding (34 patients)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Nasogastric feeding (39 patients)
Number of subjects: 73
Study: 10064759

Group type: EXPERIMENTAL
Intervention: Chest physiotherapy (prophylactic)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (no chest physiotherapy)
Number of subjects: 80
Study: 7472662

Group type: EXPERIMENTAL
Intervention: Linoleic acid supplementation (10 g/d from the 20th week of gestation until delivery)
Number of subjects: 21

Group type: COMPARATOR
Intervention: LL-control group (n = 22)
Number of subjects: 21

Group type: COMPARATOR
Intervention: HL-control group (n = 21)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Linoleic acid supplementation
Number of subjects: 21

Group type: COMPARATOR
Intervention: LL-control group
Number of subjects: 21
Study: 2318517

Group type: EXPERIMENTAL
Intervention: Low dose hydrochlorothiazide (25-50 mg)
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: High dose hydrochlorothiazide (50-100 mg)
Number of subjects: 690

Group type: COMPARATOR
Intervention: Second drug (hydralazine, methyldopa, metoprolol, or reserpine) added to hydrochlorothiazide
Number of subjects: 690
Study: 380412

Group type: EXPERIMENTAL
Intervention: Carbuterol 3 mg
Number of subjects: 21

Group type: COMPARATOR
Intervention: Salbutamol 4 mg
Number of subjects: 21
Study: 29122360

Group type: EXPERIMENTAL
Intervention: Treatment involving 7 or more beams
Number of subjects: 709

Group type: EXPERIMENTAL
Intervention: More rigorous dose calculation algorithm
Number of subjects: 709

Group type: EXPERIMENTAL
Intervention: 7 or more beams and rigorous dose calculation
Number of subjects: 709
Study: 27921088

Group type: EXPERIMENTAL
Intervention: Intra uterine extra-amniotic misoprostol (200 µg every 4 hrs)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Vaginal misoprostol (200 µg every 4 hrs)
Number of subjects: 180
Study: 24713049

Group type: EXPERIMENTAL
Intervention: Heart rate variability (HRV) measures during SBT
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: Respiratory rate variability (RRV) measures during SBT
Number of subjects: 434

Group type: EXPERIMENTAL
Intervention: WAVE score (derived from RRV during SBT)
Number of subjects: 434
Study: 23694801

Group type: EXPERIMENTAL
Intervention: 2 mg intravenous hydromorphone bolus
Number of subjects: 334

Group type: COMPARATOR
Intervention: 1+1 hydromorphone titration protocol
Number of subjects: 334
Study: 20162528

Group type: EXPERIMENTAL
Intervention: High-volume hemofiltration (HVHF) treatment for 72 hours initiated within 2 hours after enrollment
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard medical therapy (SMT)
Number of subjects: 12
Study: 18219179

Group type: EXPERIMENTAL
Intervention: Hypercholesterolemia patients
Number of subjects: 281
Study: 16884466

Group type: EXPERIMENTAL
Intervention: Clonidine 4 microg x kg(‐1) approximately 100 min before anesthesia
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control (no clonidine premedication)
Number of subjects: 56
Study: 11391125

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 9886725

Group type: EXPERIMENTAL
Intervention: Trandolapril
Number of subjects: 292

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study: 8276647

Group type: EXPERIMENTAL
Intervention: Low dose rate brachytherapy
Number of subjects: 482

Group type: COMPARATOR
Intervention: High dose rate brachytherapy
Number of subjects: 482
Study: 2788919

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional local anaesthesia
Number of subjects: 80
Study: 17233164

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine rinse
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Essential oil mouthrinse
Number of subjects: 45

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 45
Study: 656283

Group type: EXPERIMENTAL
Intervention: Cholestyramine treatment (about 4 g three times daily)
Number of subjects: 5
Study: 31171492

Group type: EXPERIMENTAL
Intervention: Sports/exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vigorous intensity PA
Number of subjects: 0
Study: 27548839

Group type: EXPERIMENTAL
Intervention: Qigong/tai chi (QGTC)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Light exercise (LE)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Waiting list control (WL)
Number of subjects: 90
Study: 26025798

Group type: EXPERIMENTAL
Intervention: Reiki
Number of subjects: 90

Group type: COMPARATOR
Intervention: Rest without treatment (Control)
Number of subjects: 90
Study: 24491267

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy plus 3,500 IU daily of bemiparin for a maximum of 26 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Chemoradiotherapy alone
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Bemiparin
Number of subjects: 38
Study: 22157768

Group type: EXPERIMENTAL
Intervention: Peg‐IFN alfa‐2a with ribavirin
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Peg‐IFN alfa‐2b with ribavirin
Number of subjects: 260

Group type: COMPARATOR
Intervention: Peg‐IFN alfa‐2a or Peg‐IFN alfa‐2b with ribavirin
Number of subjects: 260
Study: 19303163

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: HVPG >10 mmHg
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Albumin
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Viral etiology
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: HVPG
Number of subjects: 213
Study: 17523385

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) with Betulaceae extracts
Number of subjects: 47

Group type: COMPARATOR
Intervention: Subcutaneous immunotherapy (SCIT) with Betulaceae extracts
Number of subjects: 47
Study: 15453520

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) over left motor cortex at 110% of motor threshold, using 1 Hz or 15 Hz stimulation.
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) over left prefrontal cortex at 110% of motor threshold, using 1 Hz or 15 Hz stimulation.
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sham transcranial magnetic stimulation.
Number of subjects: 8
Study: 12704887

Group type: EXPERIMENTAL
Intervention: Colonic J-pouch reconstruction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alternative methods (ileocecal reservoir, transverse coloplasty pouch, side-to-end anastomosis)
Number of subjects: 0
Study: 9657238

Group type: EXPERIMENTAL
Intervention: Acamprosate 2 g daily for 7 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7660440

Group type: EXPERIMENTAL
Intervention: Standard dose of mefloquine (750 mg at 24 h)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: High dose of mefloquine (750 mg at 24 h, then 500 mg at 30 h)
Number of subjects: 57
Study: 2757880

Group type: EXPERIMENTAL
Intervention: Nicardipine 60 mg twice daily for 28 days
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 767091

Group type: EXPERIMENTAL
Intervention: Daily thorough cleaning of dentures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shaping and preparing the denture-bearing base and its mucosal side
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical and hygienic measures
Number of subjects: 0
Study: 31513474

Group type: EXPERIMENTAL
Intervention: Normative feedback
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 130
Study: 31583921

Group type: EXPERIMENTAL
Intervention: Soy isoflavone combined with calcium
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Soy isoflavone
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Calcium
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 160
Study: 30589965

Group type: EXPERIMENTAL
Intervention: Vonoprazan (20 mg daily)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Lansoprazole (30 mg daily)
Number of subjects: 32
Study: 28231950

Group type: EXPERIMENTAL
Intervention: IgG3-β1AR-AAbs group
Number of subjects: 353

Group type: COMPARATOR
Intervention: Non-IgG3 group
Number of subjects: 353
Study: 25773009

Group type: EXPERIMENTAL
Intervention: Low dose multivitamin and mineral supplement (1× RDI for 30 days, then 2× RDI for 30 days)
Number of subjects: 66
Study: 23447043

Group type: EXPERIMENTAL
Intervention: Test formulation of indapamide
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reference formulation of indapamide
Number of subjects: 20